Read more about Biological E ties up with Canadian firm Providence for mRNA Covid vaccine on Business Standard. The vaccine, named PTX-COVID19-B, is under development in Canada; the deal assumes significance as this gives India access to the mRNA tech
Article content
Canadian scientists creating COVID-19 vaccines have a problem: too many vaccinated Canadians.
The country’s accelerating immunization campaign means domestic developers likely can’t test their product against a placebo at home, prompting some to eye overseas trials or other alternatives to prove their vaccines work.
We apologize, but this video has failed to load.
Try refreshing your browser. Canadian COVID-19 vaccine makers next challenge: testing their product Back to video
Dr. Volker Gerdts’s team at the University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) started work on a COVID-19 vaccine in January 2020. But participants in their phase one trial are dropping out as they become eligible for approved vaccines.
TORONTO A Canadian drugmaker has posted promising Phase 1 trial results for its own COVID-19 vaccine, but is threatening to move its future trials and production out of the country if it doesnât receive further support from the federal government. On Wednesday, Calgary-based Providence Therapeutics released results from its Phase 1 trials of 60 participants aged 18-64 that show âstrong virus neutralization capabilityâ with no serious side-effects reported, according to a news release. Participants in the Phase 1 trial were given either a placebo or Providenceâs vaccine in one of three dose sizes. After 28 days, participants given any of the vaccine sizes showed COVID-19 antibodies, while all doses showed 100 per cent COVID-19 âblocking activityâ after 42 days.
from Canadian Broadcasting Corporation
Sunday, May 2, 2021
COVID-19 vaccine maker Providence says it s leaving Canada after calls for more federal support go unanswered
A volunteer receives an injection in this undated handout image provided by Providence Therapeutics. (Providence Therapeutics/The Canadian Press) The head of a homegrown company behind a promising COVID-19 vaccine says he s ready to pull his company out of Canada and take its product elsewhere after calls for more substantial federal support went unanswered. Brad Sorenson, the CEO of Calgary-based Providence Therapeutics, told CBC News he s had enough of the runaround from federal and provincial governments and he s working with the company s board of directors to move its operations overseas to focus on developing a vaccine for people in the southern hemisphere.